

May 18, 2020

National Stock Exchange of India Limited  
Exchange Plaza,  
Plot No. C/1, G Block,  
Bandra Kurla Complex, Bandra (E)  
Mumbai – 400 051

BSE Limited  
Corporate Relationship Department  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai- 400001

**Subject: Press Release for Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2020.**

Dear Sir/Madam,

Please find enclosed herewith the Press Release for the Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended March 31, 2020.

Thanking You,

Yours Faithfully,

For Dr. Lal PathLabs Limited



**Rajat Kalra**  
Company Secretary and Legal Head



Encl: As above

**Dr. Lal PathLabs Limited records revenue growth of 0.2% to Rs 301.7 Cr in Q4 FY 2019-20**

**New Delhi, India, May 18, 2020** – Dr. Lal PathLabs Limited (referred to as the “Company”; NSE: LALPATHLAB, BSE: 539524), a leading diagnostic and related healthcare service provider announces their financial results for the quarter ended March 31, 2020

**Consolidated Performance Highlights: Q4 FY 2019-20 vs Q4 FY 2018-19**

**Revenue growth: 0.2% at Rs 301.7 Cr,  
Normalised EBITDA ex Ind AS 116 at Rs 55.5 Cr,  
Normalised EBITDA margins ex Ind AS 116 at 18.4%,  
PBT at Rs 45.4 Cr, and PAT Rs 32.6 Cr with margin at 10.8%**

- Operating Revenue increased by 0.2% in Q4 FY20 to Rs. 301.7 Cr vs Rs 301.1 Cr in the previous year same quarter. Underlying patient volume growth is 2.1% during the quarter
- Normalised EBITDA (after adjustment for stock based compensation, CSR cost & impact of Ind AS 116) for Q4 FY20 is at Rs. 55.5 Cr Vs Rs 72.9 Cr in the same quarter last year
- PBT is at Rs 45.4 Cr in Q4 FY20 vs Rs 69.2 Cr. in Q4 last year
- Profit after Tax in Q4 FY20 at Rs. 32.6 Cr as compared to Rs 47.4 Cr in Q4 last year

**Financial Overview (Consolidated) in Rs Cr**

Particulars	Q4 FY20 (With IND- AS 116)	Q4 FY20 (W/O IND- AS 116)	Q4 FY19 (W/O IND- AS 116)	Gr % (With IND-AS 116)	Gr % (W/O IND-AS 116)	FY20 (With IND- AS 116)	FY20 (W/O IND- AS 116)	FY19 (W/O IND- AS 116)	Gr % (With IND-AS 116)	Gr % (W/O IND-AS 116)
Revenue	301.7	301.7	301.1	0.2%	0.2%	1330.4	1330.4	1203.4	10.6%	10.6%
Expenditure	244.4	253.1	234.9			986.8	1021.3	909.8		
EBITDA	57.3	48.6	66.2	-13.4%	-26.6%	343.6	309.1	293.6	17.0%	5.3%
Adj for Stock based compensation & CSR cost	6.9	6.9	6.7			22.0	22.0	19.6		
Normalised EBITDA	64.2	55.5	72.9	-11.9%	-23.9%	365.6	331.1	313.2	16.7%	5.7%
Normalised Margins	21.3%	18.4%	24.2%			27.5%	24.9%	26.0%		
Other income	12.0	12.0	13.5			55.0	55.0	46.0		
PBT	45.4	47.5	69.2	-34.4%	-31.4%	310.5	320.0	300.6	3.3%	6.5%
Margins	15.0%	15.7%	23.0%			23.3%	24.1%	25.0%		
PAT	32.6	35.5	47.4	-31.2%	-25.1%	227.6	239.4	200.5	13.5%	19.4%
Margins	10.8%	11.8%	15.7%			17.1%	18.0%	16.7%		
EPS (Basic)	3.94		5.72	-31.1%		27.42		24.19	13.4%	
EPS (Diluted)	3.93		5.71	-31.2%		27.37		24.15	13.3%	



## About Dr. Lal PathLabs Limited

---

Dr. Lal PathLabs is a provider of diagnostic and related healthcare tests and services in India. Through its' integrated, nationwide network, the company offer patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions.

As on March 31, 2020 the company has 216 clinical laboratories (including National Reference Lab at Delhi & Regional Reference Lab at Kolkata), 3,095 Patient Service Centers (PSCs) and 6,995 Pick-up Points (PUPs). Its' customers include individual patients, hospitals and other healthcare providers and corporate customers.

## Contact Details

---

Ved Prakash Goel  
Chief Financial Officer  
*Dr. Lal PathLabs Limited*

+91 124 3016500  
[cfo@lalpathlabs.com](mailto:cfo@lalpathlabs.com)

Mittali Bharti  
*Adfactors PR*

+91 9871154558  
[mittali.bharti@adfactorspr.com](mailto:mittali.bharti@adfactorspr.com)

For further information on Dr. Lal PathLabs see [www.lalpathlabs.com](http://www.lalpathlabs.com)

---

## Safe Harbour

This release contains statements that contain “forward looking statements” including, but without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to Dr. Lal PathLabs future business developments and economic performance. While these forward looking statements indicate our assessment and future expectations concerning the development of our business, a number of risks, uncertainties and other unknown factors could cause actual developments and results to differ materially from our expectations. These factors include, but are not limited to, general market, macro-economic, governmental and regulatory trends, movements in currency exchange and interest rates, competitive pressures, technological developments, changes in the financial conditions of third parties dealing with us, legislative developments, and other key factors that could affect our business and financial performance. Dr. Lal PathLabs undertakes no obligation to publicly revise any forward looking statements to reflect future / likely events or circumstances.